JLM-BioCity Innovations - JLM-BioCity

JLM-BioCity Biotech computation artificialintelligence mmunology peptides drugdevelopment

Pepticom’s AI Discovered 53 Novel Immune-Mmodulators

December 10, 2018

Pepticom was honored with an image from their article on this December’s Journal of Immunology. The image is taken from Pepticom’s latest article “Computationally Designed Bispecific

Immunovative Therapies’ Next-Generation Cancer Vaccine Could Change the Game!

December 10, 2018

While current immunotherapies offer promise to previously untreatable cancers, they only work in a small percentage of patients with certain types of cancer. Scientists have

Enlivex Therapeutics merged into NASDAQ-based Co-Bioblast Pharma Ltd, of Dahlia Meggido

December 8, 2018

Bioblast Pharma Ltd. (Nasdaq:ORPN) announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. Upon closing of the

JLM-BioCity ehealth accelerator Hadassah Hadassit IBM

Hadasit & IBM set up digital health accelerator at Hadassah Ein Kerem, Jerusalem

December 8, 2018

Hadassah Medical Center in Jerusalem and IBM Israel have announced the establishment of a special accelerator for startups in which the startups can develop advanced

Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update

November 25, 2018

Completed enrollment in pivotal Phase 3 ACCORDANCE trial is on track for topline data in mid-2019 JERUSALEM, Nov. 9, 2018 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the

Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics

Positive results in Entera Bio’s pharmacokinetic (PK) & pharmacodynamic (PD) study in patients with hypoparathyroidism

November 25, 2018

Entera Bio Ltd. (Nasdaq: ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in

JLM-BioCIty pharma biotech flu influenza vaccine

The New Scientist Reports on Biondvax’s Universal Flu Vaccine

November 17, 2018

For decades, scientists have been trying to develop a universal vaccine that would protect people against seasonal flu for years, and also against pandemics, which

Anchiano Therapeutics files for $30-40m Nasdaq offering

November 17, 2018

Jerusalem based cancer treatment company Anchiano Therapeutics (TASE: ANCN), formerly BioCancell Therapeutics, has announced the publication of a confidential prospectus for an offering on Nasdaq. It is

Results of Zion Medical’s First Human Clinical Trial of HIV drug Gammora Offers Potential Cure

November 11, 2018

Zion Medical, an Israeli biotech company developing HIV and cancer treatments, has announced the results of the first clinical trial of HIV-drug Gammora, eliminating up

More JLM-BioCity events coming soon…

Alexander Naslednikov

Excellent organization (from the timing to food), the quality of the audience was superior, we personally got a lot of hot leads.

-Alexander Naslednikov, Founder and CEO, Med.me

Tal Or

One of the best meetups organizations and a very important source of information and connections for startups.

-Tal Or, Co-Founder, ATLASense Biomed Ltd.

Hemda Idel

Very informative and eye-opening event. Thank you for the great hospitality.

– Hemda Idel, founder, SLEEP ASAP

Aviv Marom

There was an excellent networking atmosphere with impressive Panelists as well as high-quality audience participants. I strongly recommend paying attention to future events.

-Aviv Marom, Director, Strategic Partnerships, Samsung Research, Israel

Aurélie Schwarzbach

Such an interesting lecture and great people attending!

– Aurélie Schwarzbach, Clinical Project Manager, Gamida Cell Ltd.

Zeev Malyutin

Thank you all for the great evening, it was a pleasure to see such a good and diverse set of Biomed minded people in Jerusalem!

– Zeev Malyutin, Protein Department Head, Merck KGaA

Gideon Silberman

Excellent event. Good speakers, interesting audience. Well done!

– Gideon Silberman, Director of Business Development, Partner and Co-Founder, Aneeva.com

Immanuel Lerner

I believe in the idea of JLM-BioCity. It is good that there is an organization that represents the life science companies in Jerusalem and provides an excellent platform for networking through its regular meetings.

– Immanuel Lerner CEO, Pepticom

Dror Chevion

JLM-BioCity’s events are well organized with a professional approach. You can feel a “homey” atmosphere around the people of a well-maintained bio-community in Jerusalem. Team members always make sure the guests feel welcome and connected to the right people for possible collaborations. There are clearly visible good-will and dedication to lead the members of the bio-community and the city as a whole to success.

– Dror Chevion CEO, Concenter BioPharma

Ian Solomon

The JLM BioCity networking events on Zoom keeps getting better. For OmnySense they have provided an excellent forum in which to present our company, and the break-out sessions facilitate direct discussion with a broad range of potential partners and investors.

-Ian Solomon CTO, OmnySense Ltd.

Moshe Lebowitz

Because every biotech and medtech professional knows that Jerusalem BioCity consistently delivers world-class programming, the best professionals always show up and the networking before and after the events is worth its time in gold.

– Moshe Lebowitz, CEO, Healables Digital Health | Healables: Wearables that Heal

JLM-BioCity was recently written up in THE MARKER (in Hebrew). To see the article, click here.